AMGN · News · 20260913N

Manufacturing Capacity Expansion

AMGEN INC · 2026-09-13 · Importance 17 · Surprise 24

The report identified manufacturing capacity for Amgen’s obesity drugs as a key risk to the company’s 2027 growth case. This suggests potential capacity constraints could affect the scalability of the obesity-drug opportunity. No specific facilities, production volumes, utilization rates, or expansion timelines were reported.

Key facts

• The article highlights key risks to Amgen's outlook, particularly concerning manufacturing capacity for obesity drugs. source